ENYO Pharma is a biotechnology company developing FXR agonists for the treatment of severe kidney diseases, including Alport Syndrome.

Inflammatix develops molecular diagnostic tests, including the TriVerity™ Acute Infection and Sepsis Test, to improve the detection and treatment of sepsis in emergency departments.

Caresyntax develops AI-enabled surgical software that enhances surgical outcomes by integrating and analyzing comprehensive data to support real-time and post-surgical decision-making.

Memo Therapeutics is a late-stage biotech company that has raised CHF 25M in a Series C funding round to develop its antibody, AntiBKV, and advance its existing antibody pipeline.